Jiangsu Sihuan Bioengineering Co Ltd (000518) - Net Assets
Based on the latest financial reports, Jiangsu Sihuan Bioengineering Co Ltd (000518) has net assets worth CN¥385.48 Million CNY (≈ $56.41 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥509.14 Million ≈ $74.50 Million USD) and total liabilities (CN¥123.67 Million ≈ $18.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Jiangsu Sihuan Bioengineering Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥385.48 Million |
| % of Total Assets | 75.71% |
| Annual Growth Rate | 5.71% |
| 5-Year Change | -41.76% |
| 10-Year Change | -34.45% |
| Growth Volatility | 76.78 |
Jiangsu Sihuan Bioengineering Co Ltd - Net Assets Trend (1992–2024)
This chart illustrates how Jiangsu Sihuan Bioengineering Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Jiangsu Sihuan Bioengineering Co Ltd (000518) total assets for the complete picture of this company's asset base.
Annual Net Assets for Jiangsu Sihuan Bioengineering Co Ltd (1992–2024)
The table below shows the annual net assets of Jiangsu Sihuan Bioengineering Co Ltd from 1992 to 2024. For live valuation and market cap data, see Jiangsu Sihuan Bioengineering Co Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥398.97 Million ≈ $58.38 Million |
-22.19% |
| 2023-12-31 | CN¥512.78 Million ≈ $75.04 Million |
-13.60% |
| 2022-12-31 | CN¥593.50 Million ≈ $86.85 Million |
-8.24% |
| 2021-12-31 | CN¥646.78 Million ≈ $94.64 Million |
-5.59% |
| 2020-12-31 | CN¥685.05 Million ≈ $100.24 Million |
+3.75% |
| 2019-12-31 | CN¥660.31 Million ≈ $96.62 Million |
+2.72% |
| 2018-12-31 | CN¥642.80 Million ≈ $94.06 Million |
-4.85% |
| 2017-12-31 | CN¥675.54 Million ≈ $98.85 Million |
+10.55% |
| 2016-12-31 | CN¥611.10 Million ≈ $89.42 Million |
+0.40% |
| 2015-12-31 | CN¥608.69 Million ≈ $89.07 Million |
-15.65% |
| 2014-12-31 | CN¥721.59 Million ≈ $105.59 Million |
-1.26% |
| 2013-12-31 | CN¥730.78 Million ≈ $106.94 Million |
-11.98% |
| 2012-12-31 | CN¥830.24 Million ≈ $121.49 Million |
-9.34% |
| 2011-12-31 | CN¥915.76 Million ≈ $134.00 Million |
+4.10% |
| 2010-12-31 | CN¥879.72 Million ≈ $128.73 Million |
+23.49% |
| 2009-12-31 | CN¥712.38 Million ≈ $104.24 Million |
+2.82% |
| 2008-12-31 | CN¥692.86 Million ≈ $101.39 Million |
-16.90% |
| 2007-12-31 | CN¥833.76 Million ≈ $122.01 Million |
-17.54% |
| 2006-12-31 | CN¥1.01 Billion ≈ $147.97 Million |
+0.82% |
| 2005-12-31 | CN¥1.00 Billion ≈ $146.76 Million |
-9.39% |
| 2004-12-31 | CN¥1.11 Billion ≈ $161.96 Million |
+1.02% |
| 2003-12-31 | CN¥1.10 Billion ≈ $160.34 Million |
+3.11% |
| 2002-12-31 | CN¥1.06 Billion ≈ $155.49 Million |
+8.09% |
| 2001-12-31 | CN¥983.04 Million ≈ $143.85 Million |
+379.92% |
| 2000-12-31 | CN¥204.83 Million ≈ $29.97 Million |
+30.61% |
| 1999-12-31 | CN¥156.83 Million ≈ $22.95 Million |
+50.38% |
| 1998-12-31 | CN¥104.29 Million ≈ $15.26 Million |
-45.09% |
| 1997-12-31 | CN¥189.95 Million ≈ $27.80 Million |
+5.21% |
| 1996-12-31 | CN¥180.55 Million ≈ $26.42 Million |
-13.60% |
| 1995-12-31 | CN¥208.96 Million ≈ $30.58 Million |
-8.59% |
| 1994-12-31 | CN¥228.60 Million ≈ $33.45 Million |
+8.47% |
| 1993-12-31 | CN¥210.74 Million ≈ $30.84 Million |
+211.90% |
| 1992-12-31 | CN¥67.57 Million ≈ $9.89 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Sihuan Bioengineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 73188567100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥1.03 Billion | 276.98% |
| Other Comprehensive Income | CN¥74.04 Million | 19.92% |
| Total Equity | CN¥371.71 Million | 100.00% |
Jiangsu Sihuan Bioengineering Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangsu Sihuan Bioengineering Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Perspective Therapeutics Inc.
NYSE MKT:CATX
|
$438.57 Million |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
$438.59 Million |
|
Guangzhou Tech-Long Packing Machine Co Ltd
SHE:002209
|
$438.61 Million |
|
Nanjing Res In of Surveying Mapping
SHE:300826
|
$438.66 Million |
|
Vestum AB (publ)
ST:VESTUM
|
$438.40 Million |
|
Bahnhof AB Series B
ST:BAHN-B
|
$438.23 Million |
|
Guangdong Huafeng New Energy Technology Co Ltd
SHE:002806
|
$437.78 Million |
|
OPTHEA LTD
F:UKJ
|
$437.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Sihuan Bioengineering Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 481,706,954 to 371,713,279, a change of -109,993,675 (-22.8%).
- Net loss of 109,993,675 reduced equity.
- Dividend payments of 600,347 reduced retained earnings.
- Other comprehensive income increased equity by 73,429,517.
- Other factors decreased equity by 72,829,170.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-109.99 Million | -29.59% |
| Dividends Paid | CN¥600.35K | -0.16% |
| Other Comprehensive Income | CN¥73.43 Million | +19.75% |
| Other Changes | CN¥-72.83 Million | -19.59% |
| Total Change | CN¥- | -22.83% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Sihuan Bioengineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 44.80x to 8.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1992-12-31 | CN¥0.06 | CN¥2.91 | x |
| 1993-12-31 | CN¥0.20 | CN¥2.91 | x |
| 1994-12-31 | CN¥0.22 | CN¥2.91 | x |
| 1995-12-31 | CN¥0.20 | CN¥2.91 | x |
| 1996-12-31 | CN¥0.17 | CN¥2.91 | x |
| 1997-12-31 | CN¥0.18 | CN¥2.91 | x |
| 1998-12-31 | CN¥0.10 | CN¥2.91 | x |
| 1999-12-31 | CN¥0.15 | CN¥2.91 | x |
| 2000-12-31 | CN¥0.20 | CN¥2.91 | x |
| 2001-12-31 | CN¥0.94 | CN¥2.91 | x |
| 2002-12-31 | CN¥1.02 | CN¥2.91 | x |
| 2003-12-31 | CN¥1.05 | CN¥2.91 | x |
| 2004-12-31 | CN¥1.06 | CN¥2.91 | x |
| 2005-12-31 | CN¥0.96 | CN¥2.91 | x |
| 2006-12-31 | CN¥1.26 | CN¥2.91 | x |
| 2007-12-31 | CN¥0.81 | CN¥2.91 | x |
| 2008-12-31 | CN¥0.67 | CN¥2.91 | x |
| 2009-12-31 | CN¥0.69 | CN¥2.91 | x |
| 2010-12-31 | CN¥0.69 | CN¥2.91 | x |
| 2011-12-31 | CN¥0.69 | CN¥2.91 | x |
| 2012-12-31 | CN¥0.73 | CN¥2.91 | x |
| 2013-12-31 | CN¥0.66 | CN¥2.91 | x |
| 2014-12-31 | CN¥0.66 | CN¥2.91 | x |
| 2015-12-31 | CN¥0.59 | CN¥2.91 | x |
| 2016-12-31 | CN¥0.59 | CN¥2.91 | x |
| 2017-12-31 | CN¥0.61 | CN¥2.91 | x |
| 2018-12-31 | CN¥0.58 | CN¥2.91 | x |
| 2019-12-31 | CN¥0.60 | CN¥2.91 | x |
| 2020-12-31 | CN¥0.62 | CN¥2.91 | x |
| 2021-12-31 | CN¥0.59 | CN¥2.91 | x |
| 2022-12-31 | CN¥0.54 | CN¥2.91 | x |
| 2023-12-31 | CN¥0.47 | CN¥2.91 | x |
| 2024-12-31 | CN¥0.36 | CN¥2.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Sihuan Bioengineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -54.05%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.53x
- Recent ROE (-29.59%) is below the historical average (-2.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1992 | 9.52% | 8.74% | 0.58x | 1.88x | CN¥-322.59K |
| 1993 | 9.80% | 32.76% | 0.24x | 1.22x | CN¥-414.92K |
| 1994 | 8.12% | 22.45% | 0.29x | 1.25x | CN¥-4.26 Million |
| 1995 | -6.84% | -24.16% | 0.23x | 1.25x | CN¥-35.19 Million |
| 1996 | -15.99% | -34.27% | 0.30x | 1.53x | CN¥-46.53 Million |
| 1997 | 3.12% | 2.80% | 0.69x | 1.61x | CN¥-12.79 Million |
| 1998 | -29.96% | -6152.86% | 0.00x | 1.73x | CN¥-41.67 Million |
| 1999 | 24.69% | 36.79% | 0.49x | 1.38x | CN¥23.04 Million |
| 2000 | 25.88% | 28.31% | 0.68x | 1.34x | CN¥32.53 Million |
| 2001 | 7.79% | 20.83% | 0.34x | 1.10x | CN¥-21.62 Million |
| 2002 | 8.09% | 18.23% | 0.41x | 1.08x | CN¥-20.21 Million |
| 2003 | 6.32% | 18.36% | 0.31x | 1.13x | CN¥-40.24 Million |
| 2004 | 1.02% | 3.60% | 0.22x | 1.26x | CN¥-99.11 Million |
| 2005 | -10.36% | -50.33% | 0.16x | 1.30x | CN¥-203.52 Million |
| 2006 | 0.71% | 2.55% | 0.23x | 1.22x | CN¥-93.34 Million |
| 2007 | -21.33% | -62.87% | 0.32x | 1.07x | CN¥-259.73 Million |
| 2008 | -20.30% | -77.96% | 0.23x | 1.13x | CN¥-208.78 Million |
| 2009 | 3.28% | 12.03% | 0.26x | 1.06x | CN¥-47.90 Million |
| 2010 | 1.07% | 3.67% | 0.22x | 1.34x | CN¥-63.99 Million |
| 2011 | -0.84% | -2.44% | 0.25x | 1.37x | CN¥-77.01 Million |
| 2012 | 1.35% | 3.84% | 0.29x | 1.22x | CN¥-64.52 Million |
| 2013 | -10.47% | -33.88% | 0.25x | 1.22x | CN¥-138.22 Million |
| 2014 | 0.87% | 2.47% | 0.29x | 1.20x | CN¥-62.15 Million |
| 2015 | -12.27% | -31.30% | 0.29x | 1.38x | CN¥-135.11 Million |
| 2016 | 0.73% | 1.37% | 0.32x | 1.66x | CN¥-56.64 Million |
| 2017 | 1.16% | 2.11% | 0.37x | 1.48x | CN¥-55.58 Million |
| 2018 | -4.91% | -7.44% | 0.43x | 1.55x | CN¥-89.36 Million |
| 2019 | 2.34% | 3.43% | 0.46x | 1.49x | CN¥-47.02 Million |
| 2020 | 4.26% | 5.40% | 0.61x | 1.29x | CN¥-36.79 Million |
| 2021 | -6.32% | -10.90% | 0.44x | 1.32x | CN¥-98.87 Million |
| 2022 | -9.56% | -19.72% | 0.37x | 1.32x | CN¥-109.01 Million |
| 2023 | -15.63% | -31.97% | 0.36x | 1.37x | CN¥-123.44 Million |
| 2024 | -29.59% | -54.05% | 0.36x | 1.53x | CN¥-147.17 Million |
Industry Comparison
This section compares Jiangsu Sihuan Bioengineering Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,270,737,475
- Average return on equity (ROE) among peers: -0.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | CN¥385.48 Million | 9.52% | 0.32x | $438.41 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $108.47 Million | -73.31% | 2.66x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.66 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $-14.51 Million | 0.00% | 0.00x | $443.33 Million |
| Chengzhi Shareholding Co Ltd (000990) | $930.16 Million | 5.16% | 0.80x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $3.88 Billion | 15.17% | 0.04x | $3.86 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.19 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $12.48 Billion | 6.70% | 0.16x | $5.40 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $572.48 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.55 Billion | 15.33% | 0.16x | $1.90 Billion |
About Jiangsu Sihuan Bioengineering Co Ltd
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusheng and xindelusheng, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded … Read more